Revvity Q1 revenue falls to $650 million; adjusted EPS $0.98 vs $1.01 a year ago
Revvity reported first-quarter 2024 revenue of $650 million, down from $675 million a year earlier, and adjusted EPS from continuing operations of $0.98, down from $1.01. The company reaffirmed its full-year adjusted EPS guidance of $4.55-$4.75 and organic growth guidance of 1-3%, while updating its full-year revenue guidance to $2.76-$2.82 billion to reflect foreign currency changes.
Key points
- Q1 2024 revenue $650 million vs $675 million a year earlier; organic growth (3)%
- Life Sciences revenue fell 8% to $303 million; Diagnostics was flat at $347 million
- GAAP EPS $0.21 vs $4.50 a year earlier; the prior-year figure included discontinued operations income
- Full-year 2024 adjusted EPS guidance of $4.55-$4.75 reaffirmed; revenue guidance updated to $2.76-$2.82 billion
The filing
Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 1:11 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on April 29, 2024.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.